


FORM PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. VPI/02-06	SERIAL NO. 10/616,560
	APPLICANT Mark Ledebner et al.	CONFIRMATION NO. 2794
	FILING DATE 07/09/03	GROUP 4842 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
DR	WO 01/30778 A	05/03/01	PCT				
	WO 01/72745 A	10/04/01	PCT				
	EP 1 180 518 A	02/20/02	Europe				
	WO 02/064586 A	08/22/02	PCT				
	WO 03/015776 A	02/27/03	PCT				
	WO 03/076434 A	09/18/03	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
DR	Christopher A. Lipinski et al., "Bioisosteric Prototype Design of Biaryl Imidazoyl and Triazoyl Competitive Histamine H ₂ -Receptor Antagonists", J. Med. Chem., 29, 2154-2163 (1986).

EXAMINER



DATE CONSIDERED 9/6/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.